Medtronic's Resolute Integrity DES reaches Europe
This article was originally published in Clinica
Executive Summary
Medtronic has CE marked its Resolute Integrity drug-eluting stent (DES) for sale in Europe, and has launched the device in "European and other countries outside the US that recognise the CE mark". The Minneapolis, Minnesota firm says the device is "significantly more deliverable" than the market-leading stents. Resolute Integrity shares two elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.